Psychedelics

canbud distribution corporation

Canbud Distribution

A Tri-vertical Health and Wellness Company

CBDX:CC
CSE:CBDX

Overview

CANBUD Distribution Corp. (CSE:CBDX, FSE:CD0) is a science and technology-based health and wellness company that operates a trinitarian enterprise model in the plant-based protein, psychedelic pharmaceutical and non-psychedelic nutraceutical, and hemp cannabinoids (CBD) spaces. (www.canbudcorp.com)

Welcome To Canbud: Always On The Move#canbud#cbdx$CBDX#cse#hemp#cannabis#innovation#psychedelics#plantbased#protein#canada#invest#trading#health#wellnesspic.twitter.com/4nCITayJ0Z
— Canbud Distribution Corp, CSE:CBDX (@canbudcorp) March 10, 2021

The company’s vision and mission is to become a world leader in science and technological innovations through plant and mushroom-based disruptive wellness and environmental solutions. CANBUD’s business model includes its premium plant-based nutraceuticals, psychedelic, and hemp-derived products and services.

canbud

CANBUD leverages on timely and methodical execution of its revenue generating plan across its three verticals.

canbud

Canbud announced that it has completed the acquisition of Molecular Science Corp. through a “three-cornered” amalgamation, whereby a newly-formed wholly-owned subsidiary of the Corporation amalgamated with MSC under the Business Corporations Act (Ontario) to form MSC Corp., a wholly-owned subsidiary of the Corporation.


Get access to more exclusive Psychedelics Investing Stock profiles here

Recent News

Company News

Seelos Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference

Seelos Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 2022 Jefferies Global Healthcare Conference, June 8-10, 2022 . Raj Mehra, Ph.D., Chairman and CEO and Michael Golembiewski CFO, will present on Friday, June 10th at 12:00 PM ET and host 1x1 meetings. The ...

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 2022 Jefferies Global Healthcare Conference, June 8-10, 2022 .

(PRNewsfoto/Seelos Therapeutics, Inc.)

Raj Mehra, Ph.D., Chairman and CEO and Michael Golembiewski , CFO, will present on Friday, June 10th at 12:00 PM ET and host 1x1 meetings.

The 2022 Jefferies Global Healthcare Conference is an annual gathering where over 500 public & private healthcare companies and 3,000 leading executives, institutional investors, private equity investors & VCs will address near-term and long-term investment opportunities and discuss the current trends driving healthcare in the U.S. and internationally.

Presentation webcast registration may be accessed here .

For questions about the conference, please email healthcareconference@jefferies.com .

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD), amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA), Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com , the content of which is not incorporated herein by reference.

Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

Mike Moyer
Managing Director
LifeSci Advisors, LLC
250 West 55th St., Suite 3401
New York, NY 10019
(617) 308-4306
mmoyer@lifesciadvisors.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-the-2022-jefferies-global-healthcare-conference-301545553.html

SOURCE Seelos Therapeutics, Inc.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

COMPASS Pathways to participate in upcoming Citi's Biopharma Virtual Co-Panel Day and H.C. Wainwright Global Investment Conference

COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in two upcoming events as follows: Citi’s Biopharma Virtual Co-Panel Day: panel “Mood DisordersMental Health Panel” at 11:00 am ET on 18 May 2022 HC Wainwright Global Investments Conference: presentation at 9:00 am ET on 24 ...

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in two upcoming events as follows:

  • Citi's Biopharma Virtual Co-Panel Day: panel "Mood Disorders/Mental Health Panel" at 11:00 am ET on 18 May 2022
  • HC Wainwright Global Investments Conference: presentation at 9:00 am ET on 24 May 2022

A live audio webcast of both events will be available on the "Events" page of the Investors section of the COMPASS website. A replay of the webcast will be available for 30 days following each event. For more information, please visit ir.compasspathways.com.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Optimi Health Completes Expansion Of On-Site Analytical Laboratory

Optimi Health Corp . is pleased to announce that it has completed a planned expansion of the on-site analytical laboratory at its Princeton, British Columbia facility. The on-site lab is purpose built inside one of Optimi’s EU-GMP capable 10,000 square foot, state-of-the-art indoor growing facilities dedicated to the cultivation of safe, high-quality psychedelic and functional mushrooms. Optimi Chief Science ...

Optimi Health Corp . (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), is pleased to announce that it has completed a planned expansion of the on-site analytical laboratory at its Princeton, British Columbia facility.

The on-site lab is purpose built inside one of Optimi's EU-GMP capable 10,000 square foot, state-of-the-art indoor growing facilities dedicated to the cultivation of safe, high-quality psychedelic and functional mushrooms. Optimi Chief Science Officer, Justin Kirkland, will oversee the Company's analytical operations.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

COMPASS Pathways plc announces first quarter 2022 financial results and business highlights

COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2022 and gave an update on recent progress across its business. George Goldsmith, Chairman, CEO and Co-founder, COMPASS Pathways, said, “COMPASS made great progress this quarter including a productive end-of-phase II FDA ...

-

Highlights:
  • End of phase II meeting held with FDA
  • Award of Innovation Passport as part of the UK MHRA Innovative Licensing and Access Pathway ILAP
  • Finalising phase III in TRD program design to be ready for second half of 2022
  • Pioneering collaboration with King's College London and South London and Maudsley NHS Foundation Trust, to create The Centre for Mental Health Research and Innovation in the UK
  • Cash position at 31 March 2022 of $243.7 million
  • Conference call today at 8:00am ET (1:00pm UK)

COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2022 and gave an update on recent progress across its business.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less